Head to Head Survey: Ocugen (NASDAQ:OCGN) vs. Scinai Immunotherapeutics (NASDAQ:SCNI)

Ocugen (NASDAQ:OCGN) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Ocugen and Scinai Immunotherapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	0	0	3	0	3.00
Scinai Immunotherapeutics	0	0	0	0	0.00

Ocugen presently has a consensus target price of $6.00, indicating a potential upside of 640.74%. Given Ocugen’s stronger consensus rating and higher possible upside, equities analysts clearly believe Ocugen is more favorable than Scinai Immunotherapeutics.

Insider and Institutional Ownership

10.3% of Ocugen shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 4.4% of Ocugen shares are owned by company insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Ocugen has a beta of 4.21, indicating that its stock price is 321% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500.

Earnings and Valuation

This table compares Ocugen and Scinai Immunotherapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.52 million	52.31	-$63.08 million	($0.19)	-4.26
Scinai Immunotherapeutics	$658,000.00	4.12	-$6.50 million	($9.57)	-0.30

Scinai Immunotherapeutics has lower revenue, but higher earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ocugen and Scinai Immunotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ocugen	-532.51%	-154.75%	-90.79%
Scinai Immunotherapeutics	N/A	N/A	-30.48%

About Ocugen

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.